Panelists discuss resources and strategies to help patients and caregivers cope with the initial shock of a paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, emphasizing critical points during the ...
Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...
Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...
Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs ...
Panelists discuss how dermatologic toxicities from EGFR-targeted therapies can be effectively managed through a comprehensive approach combining prophylactic measures, early interventions with oral ...
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...
"When most people hear the words palliative care, they immediately think about hospice or end-of-life care. This includes ...
ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback